T. B. Chen

发表

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.

R. Chang, V. J. Lotti, P. Chakravarty, 1991, Journal of medicinal chemistry.

Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.

R. Chang, V. Lotti, T. B. Chen, 1987, Biochemical pharmacology.

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

W. Greenlee, R. Chang, V. J. Lotti, 1993, Journal of medicinal chemistry.

Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand.

R. Chang, V. Lotti, T. B. Chen, 1992, Molecular pharmacology.

Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.

B. E. Evans, D. Veber, K. Rittle, 1990, Journal of medicinal chemistry.

In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist.

M. Bock, R. Chang, B. Lagu, 2000, European journal of pharmacology.

In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.

W. Greenlee, R. Chang, P. Kling, 1995, European journal of pharmacology.

Characterization of the binding of [125I]L-735,286: a new nonpeptide angiotensin II AT1 receptor radioligand.

R. Chang, H. Burns, N. Brenner, 1995, Life sciences.

Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.

W. Greenlee, A. Patchett, P. Chakravarty, 1994, Journal of medicinal chemistry.

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.

W. Greenlee, R. Chang, V. J. Lotti, 1993, Journal of medicinal chemistry.

Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.

M. Bock, R. Freidinger, R. Chang, 1989, Molecular pharmacology.

Neuropeptide Y (NPY) binding sites in rat brain labeled with 125I-Bolton-Hunter NPY: comparative potencies of various polypeptides on brain NPY binding and biological responses in the rat vas deferens.

R. Chang, D. Cerino, P. Kling, 1985, Life sciences.

Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids.

S. Vuk-Pavlović, M. Huzak, T. B. Chen, 1994, Cancer letters.

Specific [3H]propionyl-neuropeptide Y (NPY) binding in rabbit aortic membranes: comparisons with binding in rat brain and biological responses in rat vas deferens.

R. Chang, V. Lotti, T. B. Chen, 1988, Biochemical and biophysical research communications.

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.

B. E. Evans, D. Veber, K. Rittle, 1986, Journal of medicinal chemistry.

Two angiotensin II binding sites in rat brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide antagonists.

R. Chang, V. Lotti, K. A. Faust, 1990, Biochemical and biophysical research communications.

Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties.

R. Chang, R. Monaghan, M A Goetz, 1985, The Journal of antibiotics.

A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.

R. Chang, V. J. Lotti, P. Chakravarty, 1994, Journal of medicinal chemistry.

A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.

W. Greenlee, R. Chang, V. J. Lotti, 1993, Journal of medicinal chemistry.

Design and synthesis of novel dihydropyridine alpha-1a antagonists.

R. Chang, C. Forray, W. Wong, 1999, Bioorganic & medicinal chemistry letters.

Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.

R. Chang, V. J. Lotti, M. Maccoss, 1993, Journal of medicinal chemistry.

Characterization of specific binding of [125I]L-762,459, a selective alpha1A-adrenoceptor radioligand to rat and human tissues.

R. Chang, H. Burns, B. Francis, 1998, European journal of pharmacology.

Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesions.

R. Chang, V. J. Lotti, V. Lotti, 1983, Life sciences.

Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.

R. Chang, K. Kunkel, V. Lotti, 1986, Molecular pharmacology.

Cholecystokinin receptor mediated hydrolysis of inositol phospholipids in guinea pig gastric glands.

R. Chang, V. Lotti, T. B. Chen, 1985, Life sciences.

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.

R. Chang, P. Kling, B. Lagu, 1999, Journal of medicinal chemistry.

Nitrogen-15 NMR chemical shifts in oligopeptides coordinated to cobalt(III).

S. Vuk-Pavlović, S. Macura, A. Nikolic, 1996, Journal of inorganic biochemistry.